Stock ABOS ACUMEN PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Acumen Pharmaceuticals, Inc.

Equities

ABOS

US00509G2093

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-17 pm EDT 		5-day change 1st Jan Change
3.65 USD -2.14% Intraday chart for Acumen Pharmaceuticals, Inc. +8.63% -4.95%
May. 15 Transcript : Acumen Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 08:55 AM
May. 14 Transcript : Acumen Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 14, 2024

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Transcript : Acumen Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 08:55 AM
Transcript : Acumen Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 14, 2024
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
GL
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
GL
Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference
GL
Acumen Pharmaceuticals Doses 1st Patient in Alzheimer's Disease Drug Study
MT
Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
GL
Acumen Pharmaceuticals, Inc. Announces First Patient Dosed in Altitude-Ad, A Phase 2 Clinical Trial of Sabirnetug in Early Alzheimer?S Disease
CI
Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024
GL
AAN 2024 Poster - INTERCEPT-AD, a Phase 1 Study of Sabirnetug (ACU193): Safety, Target Engagement, and Biomarker Changes
PU
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug at American Academy of Neurology 2024 Annual Meeting
AQ
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
GL
Acumen Pharmaceuticals Signs Deal With Lonza to Manufacture Alzheimer's Treatment Drug
MT
Lonza Enters Manufacturing Agreement for Acumen’s Alzheimer’s Disease Drug Candidate
MT
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
GL
Acumen Pharmaceuticals, Inc. Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer?S Disease
CI
Acumen Pharmaceuticals Files $200 Million Mixed Shelf
MT
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Transcript : Acumen Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 26, 2024
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ABOS Stock
  4. News Acumen Pharmaceuticals, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW